A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy.
c-myc
metabolic-associated fatty liver disease (MAFLD)
metformin
oncogene
tumorigenesis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
31 Dec 2021
31 Dec 2021
Historique:
received:
11
11
2021
revised:
16
12
2021
accepted:
20
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
Metabolic-associated fatty liver disease (MAFLD) has risen as one of the leading etiologies for hepatocellular carcinoma (HCC). Oncogenes have been suggested to be responsible for the high risk of MAFLD-related HCC. We analyzed the impact of the proto-oncogene c-MYC in the development of human and murine MAFLD and MAFLD-associated HCC. alb-myc Mild obesity, spontaneous hyperlipidaemia, glucose intolerance and insulin resistance were characteristic of 36-week-old alb-myc A novel function of c-MYC in MAFLD progression was identified opening new avenues for preventative strategies.
Sections du résumé
BACKGROUND
BACKGROUND
Metabolic-associated fatty liver disease (MAFLD) has risen as one of the leading etiologies for hepatocellular carcinoma (HCC). Oncogenes have been suggested to be responsible for the high risk of MAFLD-related HCC. We analyzed the impact of the proto-oncogene c-MYC in the development of human and murine MAFLD and MAFLD-associated HCC.
METHODS
METHODS
alb-myc
RESULTS
RESULTS
Mild obesity, spontaneous hyperlipidaemia, glucose intolerance and insulin resistance were characteristic of 36-week-old alb-myc
CONCLUSIONS
CONCLUSIONS
A novel function of c-MYC in MAFLD progression was identified opening new avenues for preventative strategies.
Identifiants
pubmed: 35008356
pii: cancers14010192
doi: 10.3390/cancers14010192
pmc: PMC8750626
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : MINECO Retos
ID : SAF2016-78711, SAF2017-87919-R, PID2020-117827RB-IOO, PID2020-117941RB-IOO, PID2020-117116RB-I00
Organisme : EXOHEP-CM
ID : S2017/BMD-3727
Organisme : NanoLiver-CM
ID : Y2018/NMT-4949
Organisme : AMMF
ID : 2018/117
Organisme : COST Action
ID : CA17112 and UCM-25/2019
Organisme : La Caixa Foundation Program
ID : HR17-00601
Organisme : German Research Foundation
ID : SFB 1382-403224013/A02 and B07
Organisme : Ramón y Cajal Researchers
ID : RYC-2014-15242 and RYC-2015-17438
Organisme : programa de Financiación de Universidad Complutense de Madrid - Banco Santander,
ID : CT63/19.
Organisme : Proyectos Estratégicos-Fondos Feder
ID : PE-0451-2018
Organisme : Instituto de Salud Carlos III
ID : PI16/01842, PI19/01404 & PI19/00589
Références
Nat Genet. 2004 Dec;36(12):1306-11
pubmed: 15565109
Curr Opin Lipidol. 2005 Aug;16(4):421-7
pubmed: 15990591
Nutr Diabetes. 2012 Mar 05;2:e30
pubmed: 23449529
Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G852-8
pubmed: 16603729
Signal Transduct Target Ther. 2020 Jul 10;5(1):124
pubmed: 32651356
J Hepatol. 2016 Dec;65(6):1245-1257
pubmed: 27486010
Proc Natl Acad Sci U S A. 2018 Sep 11;115(37):9282-9287
pubmed: 30150405
J Hepatol. 2018 Oct;69(4):896-904
pubmed: 29886156
Nature. 2016 Mar 10;531(7593):253-7
pubmed: 26934227
Hepatology. 2018 Jan;67(1):123-133
pubmed: 28802062
Mol Oncol. 2018 Nov;12(11):1856-1870
pubmed: 30221473
Cancer Prev Res (Phila). 2010 Nov;3(11):1451-61
pubmed: 20947488
Oncogene. 1999 May 13;18(19):3004-16
pubmed: 10378696
Cell Mol Gastroenterol Hepatol. 2020;10(1):1-21
pubmed: 31881361
Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428
pubmed: 31028350
J Intern Med. 2014 Jul;276(1):52-60
pubmed: 24645771
Genes (Basel). 2017 Apr 19;8(4):
pubmed: 28422055
Oncogene. 1989 Jun;4(6):715-24
pubmed: 2543942
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Int J Mol Sci. 2020 Sep 16;21(18):
pubmed: 32947972
Cell Metab. 2019 Sep 3;30(3):556-572.e5
pubmed: 31447321
Cancer Res. 1993 Apr 15;53(8):1719-23
pubmed: 8467484
Gastroenterology. 2006 Oct;131(4):1262-70
pubmed: 17030195
Clin Gastroenterol Hepatol. 2012 Dec;10(12):1342-1359.e2
pubmed: 23041539
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Cell Death Dis. 2014 Jan 16;5:e996
pubmed: 24434519
Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686-90
pubmed: 24042449
Ther Adv Endocrinol Metab. 2020 May 27;11:2042018820923474
pubmed: 32523673
Carcinogenesis. 2013 Dec;34(12):2823-32
pubmed: 24130167
Ann Transl Med. 2014 Jun;2(6):57
pubmed: 25333032
Hepatobiliary Surg Nutr. 2017 Dec;6(6):401-403
pubmed: 29312975
Biochim Biophys Acta. 2013 Oct;1832(10):1765-75
pubmed: 23770341
Compr Physiol. 2017 Dec 12;8(1):1-8
pubmed: 29357123
Gastroenterology. 2017 May;152(6):1477-1491
pubmed: 28143772
J Clin Endocrinol Metab. 2011 Jun;96(6):1654-63
pubmed: 21602457
J Clin Endocrinol Metab. 2012 Jul;97(7):2347-53
pubmed: 22523334
Nature. 2009 Apr 9;458(7239):762-5
pubmed: 19219026
Mol Ther Oncolytics. 2020 Jun 24;18:282-294
pubmed: 32728616
Cell Metab. 2020 Mar 3;31(3):605-622.e10
pubmed: 32084378
Cancers (Basel). 2021 Sep 06;13(17):
pubmed: 34503295
Hepatology. 2016 Mar;63(3):827-38
pubmed: 26599351
J Hepatol. 2016 Mar;64(3):628-40
pubmed: 26576483